0000000000353857

AUTHOR

Benjamin Goeppert

showing 4 related works from this author

Differential expression of the tumor suppressor A-kinase anchor protein 12 in human diffuse and pilocytic astrocytomas is regulated by promoter methy…

2013

The scaffold protein A-kinase anchor protein 12 (AKAP12) exerts tumor suppressor activity and is downregulated in several tumor entities. We characterized AKAP12 expression and regulation in astrocytomas, including pilocytic and diffusely infiltrating astrocytomas. We examined 194 human gliomas and 23 normal brain white matter samples by immunohistochemistry or immunoblotting for AKAP12 expression. We further performed quantitative methylation analysis of the AKAP12 promoter by MassARRAY® of normal brain, World Health Organization (WHO) grade I to IV astrocytomas, and glioma cell lines. Our results show that AKAP12 is expressed in a perivascular distribution in normal CNS, strongly upregula…

AdultMalePathologymedicine.medical_specialtyAdolescent2804 Cellular and Molecular NeuroscienceA Kinase Anchor ProteinsCell Cycle Proteins610 Medicine & healthAstrocytomaBiologyPathology and Forensic MedicineCellular and Molecular NeuroscienceGliomamedicineHumansChildPromoter Regions GeneticneoplasmsAgedAged 80 and overRegulation of gene expressionPilocytic astrocytomaBrain NeoplasmsInfantAstrocytomaGeneral MedicineMethylationDNA MethylationMiddle AgedAKAP12medicine.diseaseUp-Regulationnervous system diseases10040 Clinic for NeurologyGene Expression Regulation Neoplastic2734 Pathology and Forensic Medicine2728 Neurology (clinical)nervous systemNeurologyChild Preschool2808 NeurologyDNA methylationCancer researchImmunohistochemistryFemaleNeurology (clinical)Neoplasm Grading
researchProduct

Mandibular Brown Tumor as a Result of Secondary Hyperparathyroidism: A Case Report with 5 Years Follow-Up and Review of the Literature

2021

Background: Brown tumor is a rare skeletal manifestation of secondary hyperparathyroidism. Although diagnosis of the disease is increasingly seen in early stages due to improved screening techniques, some patients still present in a progressed disease stage. The treatment depends on tumor mass and varies from a conservative approach with supportive parathyroidectomy to extensive surgical resection with subsequent reconstruction. Case presentation: We report a case of extensive mandibular brown tumor in a patient with a history of systemic lupus erythematosus, chronic kidney disease, and secondary hyperparathyroidism. Following radical resection of the affected bone, reconstruction could be …

Parathyroidectomymedicine.medical_specialtyHealth Toxicology and Mutagenesismedicine.medical_treatment030232 urology & nephrologyCase Reportradical resectionDiseaseFree flap03 medical and health sciencesjaw0302 clinical medicinesecondary hyperparathyroidismmedicineStage (cooking)microvascular reconstructionbusiness.industryRPublic Health Environmental and Occupational Health030206 dentistrymedicine.diseasebrown tumorSurgeryBrown tumorMedicineSecondary hyperparathyroidismbusinessRadical resectionKidney diseaseInternational Journal of Environmental Research and Public Health
researchProduct

Nuclear Translocation of RELB Is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice.

2019

Background & Aims Cholangiocyte proliferation and ductular reaction contribute to the onset and progression of liver diseases. Little is known about the role of the transcription factor nuclear factor-κB (NF-κB) in this process. We investigated the activities of the RELB proto-oncogene NF-κB subunit in human cholangiocytes and in mouse models of liver disease characterized by a ductular reaction. Methods We obtained liver tissue samples from patients with primary sclerosing cholangitis, primary biliary cholangitis, hepatitis B or C virus infection, autoimmune hepatitis, alcoholic liver disease, or without these diseases (controls) from a tissue bank in Germany. Tissues were analyzed by immu…

0301 basic medicineLiver CirrhosisMaleAlcoholic liver diseaseCholangiocyte proliferationAutoimmune hepatitisProto-Oncogene MasLiver diseaseMice0302 clinical medicineCarbon TetrachlorideCells CulturedRELBLiver DiseasesGastroenterologyMiddle Aged3. Good healthDeubiquitinating Enzyme CYLDCysteine EndopeptidasesProtein TransportLiverGene Knockdown TechniquesCytokines030211 gastroenterology & hepatologyFemaleCell activationAdultLymphotoxin-betaAdolescentCholangitis SclerosingPrimary sclerosing cholangitis03 medical and health sciencesYoung AdultLymphotoxin beta ReceptormedicineAnimalsHumansRNA MessengerParenchymal TissueAgedCell ProliferationCell NucleusHepatologybusiness.industryTranscription Factor RelBEpithelial CellsDicarbethoxydihydrocollidinemedicine.diseaseFibrosis030104 developmental biologyCancer researchLiver functionBile DuctsbusinessGastroenterology
researchProduct

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker…

2017

Abstract Background Combination chemotherapy has shown benefit in the treatment of biliary cancer and further improvements might be achieved by the addition of a biological agent. We report here the effect of chemotherapy with the monoclonal EGFR antibody panitumumab as therapy for KRAS wild-type biliary cancer. Patients and methods Patients with advanced biliary tract cancer were randomised (2:1) to receive cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 on day 1 and day 8/q3w with (arm A) or without panitumumab (arm B; 9 mg/kg BW, i.v q3w). The primary end-point was the evaluation of progression-free survival (PFS) at 6 months. Secondary end-points included objective response rate (ORR), ov…

MaleOncologyCancer ResearchTime Factorsmedicine.medical_treatmentMedizinKaplan-Meier Estimatemedicine.disease_causeDeoxycytidine0302 clinical medicineRisk FactorsGermanyAntineoplastic Combined Chemotherapy ProtocolsMedicinePrecision MedicineAged 80 and overPanitumumabAntibodies MonoclonalCombination chemotherapyMiddle AgedIsocitrate DehydrogenaseBiliary Tract NeoplasmsTreatment OutcomeOncology030220 oncology & carcinogenesisDisease ProgressionBiomarker (medicine)Female030211 gastroenterology & hepatologyKRASmedicine.drugAdultmedicine.medical_specialtyAdolescentDisease-Free SurvivalProto-Oncogene Proteins p21(ras)Young Adult03 medical and health sciencesInternal medicineBiomarkers TumorHumansPanitumumabAgedCisplatinChemotherapybusiness.industryGene Expression ProfilingGemcitabineGemcitabineClinical trialMutationCisplatinbusinessEuropean Journal of Cancer
researchProduct